Reference Interval:
By report
|
| Interpretive Data: |
For quality assurance purposes, ARUP Laboratories will confirm the above result at no charge following delivery. Order Confirmation of Fetal Testing and include a copy of the original fetal report (or the mother's name and date of birth) with the test submission. Please contact an ARUP genetic counselor at (800) 242-2787 extension 2141 prior to specimen submission.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
Refer to Statement C under Testing Information at http://www.aruplab.com.
|
| Note: |
Documentation of the familial gene mutation(s) is required to perform targeted sequencing. Submit a copy of a relative's laboratory test report documenting the gene and specific mutation(s) for which testing is requested.
This test is available for genes currently sequenced at ARUP.
Submit a positive control with the patient specimen for appropriate interpretation. Disease-specific patient history forms are available at www.aruplab.com/Testing-Information/consentforms-patienthistory.jsp
|
| CPT Code(s): |
83891 Isolation; 83898 Amplification; 83904 Sequencing; 83909 Capillary electrophoresis; 83912 Interpretation and report. Add the following for each additional mutation: 83898 Amplification; 83904 Sequencing. FCC: 83900 Multiplex amplification; 83901 x14 Additional amplification; 83909 Capillary electrophoresis. If MCC Maternal Cell (0050608) is performed, add: 83891 Isolation; 83900 Multiplex amplification; 83901 x14 Additional amplification; 83909 Capillary electrophoresis; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
|
Cross References: |
Alpha Globin (HBA1 and HBA2) (Familial Mutation, Targeted Sequencing, Fetal)
, Alport Syndrome, X-linked (COL4A5) (Familial Mutation, Targeted Sequencing, Fetal)
, Beta Globin (HBB) (Familial Mutation, Targeted Sequencing, Fetal)
, Carnitine Deficiency, Primary (SLC22A5) (Familial Mutation, Targeted Sequencing, Fetal)
, Connexin 26 (GJB2) (Familial Mutation, Targeted Sequencing, Fetal)
, Cystic Fibrosis (CFTR) (Familial Mutation, Targeted Sequencing, Fetal)
, Galactosemia (GALT) (Familial Mutation, Targeted Sequencing, Fetal)
, Hemophilia A (F8) (Familial Mutation, Targeted Sequencing, Fetal)
, Hemophilia B (F9) (Familial Mutation, Targeted Sequencing, Fetal)
, Hereditary Hemorrhagic Telangiectasia (ACVRL1 and ENG) (Familial Mutation, Targeted Sequencing, Fetal)
, HHT (ACVRL1 and ENG) (Familial Mutation, Targeted Sequencing, Fetal)
, Noonan Syndrome (PTPN11) (Familial Mutation, Targeted Sequencing, Fetal)
, Rett Syndrome (MECP2) (Familial Mutation, Targeted Sequencing, Fetal)
, Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (ACADVL) (Familial Mutation, Targeted Sequencing, Fetal)
|
![[ image for: Patient History for Fetal Molecular Testing]](icon_29.jpg){kind=icon}